9 Result(s)
-
Article
Open AccessLongitudinal associations of diurnal rest-activity rhythms with fatigue, insomnia, and health-related quality of life in survivors of colorectal cancer up to 5 years post-treatment
There is a growing population of survivors of colorectal cancer (CRC). Fatigue and insomnia are common symptoms after CRC, negatively influencing health-related quality of life (HRQoL). Besides increasing phys...
-
Article
Open AccessFecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer
Gut bacteria-derived short-chain fatty acids (SCFA) and branched-chain fatty acids (BCFA) are considered to have beneficial metabolic, anti-inflammatory as well as anti-carcinogenic effects. Previous preclinic...
-
Article
Open AccessCannabinoid consumption among cancer patients receiving systemic anti-cancer treatment in the Netherlands
Despite the inconclusiveness regarding health effects of cannabinoids among cancer patients, studies from non-European countries suggest that the medical-intended consumption of such products by this patient g...
-
Article
Open AccessThe fear of cancer recurrence and progression in patients with pancreatic cancer
It is plausible that patients with pancreatic cancer experience fear of tumor recurrence or progression (FOP). The aim of this study was to compare FOP in patients with pancreatic cancer treated with surgical ...
-
Article
Open AccessNerve fibers in the tumor microenvironment in neurotropic cancer—pancreatic cancer and cholangiocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are both deadly cancers and they share many biological features besides their close anatomical location. One of the main histological featur...
-
Article
Open AccessIncreased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Addition of trastuzumab to first-line palliative chemotherapy in gastroesophageal cancer patients with HER2 overexpression has shown to improve survival. Real-world data on HER2 assessment and administration o...
-
Article
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment
Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in patients with mild or moderate renal impairment to pr...
-
Article
Open AccessEffect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on corrected QT interval using Fridericia...
-
Article
Open AccessPreoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
Pancreatic cancer is the fourth largest cause of cancer death in the United States and Europe with over 100,000 deaths per year in Europe alone. The overall 5-year survival ranges from 2–7 % and has hardly imp...
